PHARMACEUTICAL IP

  • Our Offering
    • Fractional IP counsel
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional IP counsel
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional IP counsel
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional IP counsel
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional IP counsel
  • Sectors
  • Evolve Insights
  • Our team
  • Join us
  • Our offering
  • Fractional IP counsel
  • Sectors
  • Evolve Insights
  • Our team
  • Join us

Construing the claims to include technical effects mentioned in the description (T 1924/20)

  • Sector: Biotechnology
  • 8th May 2023
When it comes to interpreting patent claims, the European Patent Office is sending mixed signals. A new decision, T 1924/20, adds fuel to the fire, making a referral to the Enlarged Board of Appeal more necessary than ever.

Originally published on IPKat.

Claim interpretation is the current hot-topic at the EPO, specifically the extent to which the description should be taken into account in claim interpretation. The EPO has recently taken a hard line against using the description to narrow the meaning of clear language in the claims. There is, however, another line of recent EPO case law which has taken a similarly hard line on requiring the description to be amended in line with the claims. According to these Board of Appeal decisions, inconsistencies between the claims and the description would confuse the skilled person over how to interpret the claim language. To this Kat, these lines of case law are incompatible: either clear language in the claims should be interpreted in view of the description, or it should not, the EPO cannot have it both ways. To complicate things further, there is also mounting Boards of Appeal case law finding the contrary position on description amendments, i.e. that the description does not have to be amended in line with the claims. 

It is thus becoming increasingly clear that a referral to the Enlarged Board of Appeal on claim interpretation is necessary to harmonise Boards of Appeal case law. In this context, the recently published Board of Appeal decision in T 1924/20 adds further weight to the line of Boards of Appeal case law that the description is irrelevant to the interpretation of otherwise clear claim language.

Construing the claims to incorporate a functional effect from the description

The decision in T 1924/20 is interesting for its rejection of an approach to claim interpretation whereby functional effects mentioned in the description may be incorporated into the claims via judicious construction of the claim language. The patent in question (EP2898704) related to a hearing aid that could be worn for several months or years without being taken out, and a method of manufacturing hearing aids. The problem to be solved by an “extended wear” hearing aid of this type was how to protect the hearing aid’s electronics from prolonged exposure to ear fluids. The patent was opposed for lack of inventive step.

The Patentee’s defence relied upon a claim construction based on the description of the patent. The granted claim specified a method of manufacturing a hearing aid comprising encapsulating the electronic module. The Patentee argued that this encapsulating step would necessarily lead to a reduction in the chance of moisture reaching the electronics of the device, and that the prior art did not disclose such a step. In support of their claim interpretation the Patentee pointed to passages in the description of the patent stating that the position of the electronics module in the hull of the device “reduced the chance of moisture breaching the capsulation”. 

The Board of Appeal was not convinced by the Patentee’s arguments. The Board of Appeal argued that the passages of the description cited by the Patentee could not change the interpretation of the claim Particularly, the Board of Appeal dismissed an approach to claim interpretation that incorporated limitations from the description, finding that ‘a skilled reader of a patent claim would, for many reasons, interpret the claims based essentially on their own merits […] This is because the “subject-matter of the European patent” (cf. Article 100(a) EPC) is defined by the claims and only by them’. 

The Board of Appeal also cited with approval the reasoning from the Boeing catastrophic comma loss case (T 1127/16). In Boeing, the Board of Appeal found that it was not possible for the patentee to have recourse to the description in order to overcome an added matter objection resulting from the loss of a single comma from the claims. The Board of Appeal particularly found in Boeing that the description could not be used to change the meaning of otherwise clear language in the claims. The Board of Appeal in the present case agreed with this reasoning, finding that “when interpreting the claims, the description and drawings cannot be relied on as a sort of fall-back or supplementary-guidance tool for filling up gaps or for resolving inconsistencies in a claim to the patent proprietor’s advantage”. 

The appeal was therefore set aside and the patent revoked. Interestingly, the Patentee did not seek to rescue the patent by incorporating the functional limitation into the claims. 

Analysis

T 1924/20 is yet another Board of Appeal decision to add to the pile of recent case law finding against a role for the description in claim interpretation (see also T 0821/20). In all of these cases, the decisions have gone against Patentees arguing for a different interpretation of the claims based on the description in order to overcome an added matter or inventive step objection. The EPO has thus taken a hard line against the particular use of the description to narrow the meaning of the claim language. It will be interesting to see whether in infringement actions, a similarly hard line will be taken against the attempts of alleged infringers to narrow the claims in arguments of non-infringement. 

Related insights...

New referral on claim interpretation and relevance of G1/24 to added matter confirmed (G1/26)

  • 23rd July 2026
We now have confirmation of a new referral to the EBA on claim interpretation (G1/26). As previously hinted, The Board of Appeal in T 0873/24 has decided to refer questions on the application of G1/24 to the assessment of added matter.

When do you file for a drug combination invention? (T592/24)

  • 16th July 2026
Drug combination inventions are increasingly difficult to protect. File too early for a drug-combination invention and the application may lack the data to support the non-obvious effect of the combination. Wait for the trial read-out, and a competitor, or your own published protocol, may have already placed the invention in the public domain. 

Patenting the use of medical devices (T0941/24)

  • 26th June 2026
Patenting medical devices in Europe is challenging. First, there is the problem that medical use claims are not permitted for medical devices, whilst simultaneously methods of treatment or surgery using a device are excluded from patentability. 

BREAKING: Imminent new referral to the EBA on the relevance of G1/24 to added matter

  • 6th May 2026
The Board of Appeal in T 873/24 has decided to refer questions to the Enlarged Board of Appeal (EBA) on the application of G1/24 (claim interpretation) to the assessment of added matter.

Description amendments can extend protection (T 439/22)

  • 3rd April 2026
The comments space for the last IPKat article on claim interpretation/description amendments appears to have maxed out. Sorry everyone, but maybe it’s for the best. However, fear not, we now have a new decision to restart the debate!

The validity and value of cell therapy safety protocol inventions (T 1555/23)

  • 11th March 2026
The patent in T 1555/23 is impressively broad. The claims covered a medical use invention comprising treating the side effects of CAR-T cell therapy using the now industry-standard class of cytokine inhibitor. The claim was not limited to any particular CAR-T cell therapy, target, type of cancer or specific inhibitor.

G 1/25 (description amendments) amicus curiae: The battle lines are drawn

  • 4th March 2026
If you want to start an argument amongst European patent attorneys, just mention description amendments. As the comments on this and other blogs attest, adaptation of the description is a highly divisive issue and the debate can get decidedly heated (with our US colleagues looking on with bemusement).

Mechanistic insights supporting the sufficiency and inventive step of a therapeutic use (without clinical data) (T 1601/22)

  • 24th February 2026
At the EPO, it is perfectly possible for a therapeutic invention to survive without clinical data. The recent decision in T 1601/22 confirmed this sometimes surprisingly low bar for sufficiency in Europe for therapeutic invention.

Non-reproducible products can be the closest prior art (T 1719/21)

  • 17th February 2026
G 1/23 establishes that products made available to the public are prior art in Europe, regardless of reproducibility. While this simplifies novelty, focusing strictly on disclosure dates, it complicates inventive step assessments. Notably, T 1719/21 questions whether these non-reproducible products can serve as the “closest prior art” in the EPO’s problem-solution approach.

ViCo oral proceedings: Whatever happened to the in-person “Gold-Standard”?

  • 14th December 2025
We are now many years on from the pandemic conditions that initially led to the introduction of oral proceedings by video conferencing for Board of Appeal cases. But what happened to the “Gold Standard” of in-person proceedings promised by the EBA in G 1/21? 
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

Subscribe

Contact Us